Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials

• Authors: Behzad Elahi , Shekoufeh Nikfar , Saeed Derakhshani , Mohammad Vafaie , Mohammad Abdollahi
• Languages of publication: EN

Abstracts

EN

The aim of the study was to evaluate and collect current evidence on the effect of antibiotics in pretreatment of pouchitis after restorative ileal pouch anal anastomosis (IPAA). Pubmed, Embase, Web of Science, Scopus, and Cochrane Library databases were searched between 1966 and July 2008; and relevant clinical trials extracted, reviewed, and validated according to the study protocol. The outcome of interest was clinical improvement after treatment. Nine randomized, placebo-controlled clinical trials were found relevant and studied but 3 of them with 70 patients were entered into meta-analysis. Pooling of the results from these trials yielded an odds ratio of 15.96 with a 95% CI of 4.20–60.70, indicating a significant OR (p<0.0001) in treatment group in comparison to the placebo group. In conclusion, the meta-analysis confirms benefit of antibiotics in management of pouchitis after IPAA operation.

Keywords

EN

Meta-analysis; Ileal pouch anal anastomosis; Antibiotic; Pouchitis

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2009
• Volume: 4
• Issue: 2
• Pages: 164-170

Dates

published

1 - 6 - 2009

online

27 - 3 - 2009

Contributors

author

Behzad Elahi

• Division of Neurology, Institute of Medical Sciences, University of Toronto, Toronto, M5S 1A8, Canada

author

Shekoufeh Nikfar

• Food and Drug Affairs, and Food & Drug Laboratory Research Center, Ministry of Health & Medical Education, Tehran, 1314715311, Iran

author

Saeed Derakhshani

• Baharan Coloproctology Surgical Clinic, Tehran, 1516633115, Iran

author

Mohammad Vafaie

• Baharan Coloproctology Surgical Clinic, Tehran, 1516633115, Iran

author

Mohammad Abdollahi

• Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, 1417614411, Iran

References

• [1] Pricolo V.E., Ileal pouch-anal anastomosis: the ideal operation for ulcerative colitis and adenomatous polyposis coli? R. I. Med., 1994, 77, 382–384
• [2] Blumberg D., Beck D.E., Surgery for ulcerative colitis, Gastroenterol. Clin. North Am., 2002, 31, 219–235 [Crossref]
• [3] Aziz O., Athanasiou T., Fazio V.W., Nicholls R.J., Darzi A.W., Church J., et al., Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis, Br. J. Surg., 2006, 93, 407–417 http://dx.doi.org/10.1002/bjs.5276[Crossref]
• [4] Keighley M.R., Review article: the management of pouchitis. Aliment. Pharmacol. Ther., 1996, 10, 449–457 http://dx.doi.org/10.1046/j.1365-2036.1996.32174000.x[Crossref]
• [5] Nicholls R.J., Belliveau P., Neill M., Wilks M., Tabaqchali S., Restorative proctocolectomy with ileal reservoir: a pathophysiological assessment, Gut, 1981, 22, 462–468 http://dx.doi.org/10.1136/gut.22.6.462[Crossref]
• [6] Zuccaro G.Jr., Fazio V.W., Church J.M., Lavery I.C., Ruderman W.B., Farmer R.G., Pouch ileitis, Dig. Dis. Sci., 1989, 34, 1505–1510 http://dx.doi.org/10.1007/BF01537101[Crossref]
• [7] Tytgat G.N., van Deventer S.J., Pouchitis, Int. J. Colorectal Dis., 1988, 3, 226–228 http://dx.doi.org/10.1007/BF01660720[Crossref]
• [8] Simchuk E.J., Thirlby R.C., Risk factors and true incidence of pouchitis in patients after ileal pouchanal anastomoses, World J. Surg., 2000, 24, 851–856 http://dx.doi.org/10.1007/s002680010136[Crossref]
• [9] Kmiot W.A., Youngs D., Tudor R., Thompson H., Keighley M.R., Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis, Br. J. Surg. 1993, 80, 1445–1449 http://dx.doi.org/10.1002/bjs.1800801132[Crossref]
• [10] Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease, Clin. Ther., 2006, 28, 1983–1988 http://dx.doi.org/10.1016/j.clinthera.2006.12.012[Crossref]
• [11] Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of antibiotic therapy for active ulcerative colitis, Dig. Dis. Sci., 2007, 52, 2920–2925 http://dx.doi.org/10.1007/s10620-007-9760-1[Crossref][WoS]
• [12] Baker D.E., Rifaximin: a nonabsorbed oral antibiotic, Rev. Gastroenterol. Disord., 2005, 5, 19–30
• [13] Ewaschuk J.B., Tejpar Q.Z., Soo I., Madsen K., Fedorak R.N., The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease, Curr. Gastroenterol. Rep., 2006, 8, 486–498 http://dx.doi.org/10.1007/s11894-006-0039-z[Crossref]
• [14] Gionchetti P., Rizzello F., Lammers K.M., Morselli C., Sollazzi L., Davies S., et al., Antibiotics and probiotics in treatment of inflammatory bowel disease, World J. Gastroenterol., 2006, 12, 3306–3313
• [15] Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al., Antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach, Eur. Rev. Med. Pharmacol. Sci., 1999, 3, 27–30
• [16] Sachar D.B., How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis., 1998, 4, 165–166 http://dx.doi.org/10.1002/ibd.3780040212[Crossref]
• [17] Sandborn W.J., McLeod R., Jewell D.P., Medical therapy for induction and maintenance of remission in pouchitis: a systematic review, Inflamm. Bowel Dis. 1999, 5, 33–39 [Crossref]
• [18] Madden M.V., McIntyre A.S., Nicholls R.J., Doubleblind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis, Dig. Dis. Sci., 1994, 39, 1193–1196 http://dx.doi.org/10.1007/BF02093783[Crossref]
• [19] Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al., Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial, Aliment. Pharmacol. Ther. 2002, 16, 27–34 http://dx.doi.org/10.1046/j.1365-2036.2002.01139.x[Crossref]
• [20] Shen B., Fazio V., Remzi F., Bennett A., Lopez R., Brzezinski A., et al., Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis, Dis. Col. Rectum., 2007, 50, 498–508 http://dx.doi.org/10.1007/s10350-006-0828-3[Crossref][WoS]
• [21] Isaacs K.L., Sandler R.S., Abreu M., Picco M.F., Hanauer S.B., Bickston S.J., et al., Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study, Inflamm. Bowel Dis., 2007, 13, 1250–1255 http://dx.doi.org/10.1002/ibd.20187[Crossref]
• [22] Shen B., Achkar J.P., Lashner B.A., Ormsby A.H., Remzi F.H., Brzezinski A., et al., A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis, Inflamm. Bowel Dis., 2001, 7, 301–305 http://dx.doi.org/10.1097/00054725-200111000-00004[Crossref]
• [23] Nygaard K., Bergan T., Bjorneklett A., Hoverstad T., Lassen J., Aase S., Topical metronidazole treatment in pouchitis, Scand. J. Gastroenterol., 1994, 29, 462–467 http://dx.doi.org/10.3109/00365529409096839[Crossref]
• [24] Egger M., Smith G.D., Phillips A.N., Meta-analysis: principles and procedures, B. M. J., 1997, 315, 1533–1537
• [25] Abdelrazeq A.S., Kelly S.M., Lund J.N., Leveson S.H., Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis, Colorectal Dis., 2005, 7, 182–186 http://dx.doi.org/10.1111/j.1463-1318.2004.00746.x[Crossref]
• [26] Abitbol V., Chaussade S., Pouchitis after ileal pouchanal anastomosis. Gastroenterol. Clin. Biol., 1997, 21, 299–304
• [27] Becker J.M., Stucchi A.F., Bryant D.E., How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis., 1998, 4, 167–169 http://dx.doi.org/10.1002/ibd.3780040213[Crossref]
• [28] Gerard L., Garey K.W., DuPont H.L., Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections, Expert. Rev. Anti. Infect. Ther., 2005, 3, 201–211 http://dx.doi.org/10.1586/14787210.3.2.201[Crossref]
• [29] Gionchetti P., Amadini C., Rizzello F., Venturi A., Poggioli G., Campieri M., Diagnosis and treatment of pouchitis, Best Pract. Res. Clin. Gastroenterol., 2003, 17, 75–87 http://dx.doi.org/10.1053/bega.2002.0348[Crossref]
• [30] Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al., Four-week openlabel trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis, Aliment. Pharmacol. Ther., 2002, 16, 909–917 http://dx.doi.org/10.1046/j.1365-2036.2002.01203.x[Crossref]
• [31] Madiba T.E., Bartolo D.C., Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J. R. Coll. Surg. Edinb., 2001, 46, 334–337
• [32] Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al., Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis, Aliment. Pharmacol. Ther., 1999, 13, 713–718 http://dx.doi.org/10.1046/j.1365-2036.1999.00553.x[Crossref]
• [33] Shen B., Remzi F.H., Lopez A.R., Queener E., Rifaximin for maintenance therapy in antibioticdependent pouchitis, BMC Gastroenterol., 2008, 23, 26 http://dx.doi.org/10.1186/1471-230X-8-26[Crossref][WoS]
• [34] Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al., Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial, Gastroenterology, 2003, 124, 1202–1209 http://dx.doi.org/10.1016/S0016-5085(03)00171-9[Crossref]
• [35] Elahi B., Nikfar S., Derakhshani S., Vafaie M., Abdollahi M., Benefit of probiotics in the control of pouchitis in patients underwent ileal pouch anal anastomosis operation; A meta-analysis of controlled clinical trials, Dig. Dis. Sci., 2007, 53, 1278–1284 http://dx.doi.org/10.1007/s10620-007-0006-z[WoS][Crossref]
• [36] Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al., Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial, Aliment. Pharmacol. Ther., 2002, 16, 27–34 http://dx.doi.org/10.1046/j.1365-2036.2002.01139.x[Crossref]
• [37] Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Peruzzo S., et al., Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis, Aliment. Pharmacol. Ther., 1997, 11, 673–678 http://dx.doi.org/10.1046/j.1365-2036.1997.00217.x[Crossref]
• [38] Wischmeyer P., Pemberton J.H., Phillips S.F., Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study, Mayo Clin. Proc., 1993, 68, 978–981 [Crossref]
• [39] Levin K.E., Pemberton J.H., Phillips S.F., Zinsmeister A.R., Pezim M.E., Role of oxygen free radicals in the etiology of pouchitis. Dis. Colon Rectum, 1992, 35, 452–456 http://dx.doi.org/10.1007/BF02049401[Crossref]
• [40] Hurst R.D., Molinari M., Chung T.P., Rubin M., Michelassi F., Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy, Arch. Surg., 1996, 131, 497–500 [Crossref]
• [41] Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission, Arch. Med. Sci. 2008, 4, 185–190
• [42] Rahimi R., Nikfar S., Rahimi F., Elahi B., Derakhshani S., Vafaie M., et al., A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease, Dig. Dis. Sci., 2008, 53, 2524–2531 http://dx.doi.org/10.1007/s10620-007-0171-0[Crossref][WoS]
• [43] Nikfar S., Rahimi R., Rahimi F., Derakhshani S., Abdollahi M., Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials, Dis. Col. Rectum, 2008, 51, 1775–1780 http://dx.doi.org/10.1007/s10350-008-9335-z[Crossref]
• [44] Fric P., Probiotics and prebiotics; resistance of a therapeutic principle, Cent. Eur. J. Med., 2007, 2, 237–270. http://dx.doi.org/10.2478/s11536-007-0031-5[WoS][Crossref]
• [45] Rahimi R., Nikfar S., Abdollahi M., Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials, Arch. Med. Sci., 2008, 4, 71–76
• [46] Talley N.J., Newer antidepressants in irritable bowel syndrome: what is the evidence? Arch. Med. Sci., 2008, 4, 77–78.
• [47] Rahimi R., Nikfar S., Abdollahi M., Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids, Med. Sci. Monit., 2007, 13, PI13–PI18
• [48] Rahimi, R., Nikfar, S., Abdollahi M., Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials, Biomed. Pharmacother., 2007, 61, 75–80 http://dx.doi.org/10.1016/j.biopha.2006.06.022[WoS][Crossref]
• [49] Hosseini-Tabatabaei A., Abdollahi M., Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm. Allergy Drug Targets, 2008, 7, 129–135 http://dx.doi.org/10.2174/187152808785748164[Crossref]
• [50] Rezaie A., Parker R.D., Abdollahi M., Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci., 2007, 52, 2015–2021 http://dx.doi.org/10.1007/s10620-006-9622-2[Crossref][WoS]

Identifiers

DOI

10.2478/s11536-009-0019-4